Evidence map›Paper›PMID 41313431›Full record

SynthesisObesity surgery2025

Effects of Semaglutide and Tirzepatide on Recurrent Weight Gain After Bariatric Surgery: A Systematic Review and Meta-analysis.

Angel Alois Osorio Manyari, Azucena Lirio Armas Alvarez, Joel Davis Osorio Manyari, Francisco Onieva Gonzalez, Sjaak Pouwels

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Obesity surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Angel Alois Osorio ManyariService of Surgery, Hospital Don Benito-Villanueva, Don Benito, Spain. aloisosorio@hotmail.com.
Azucena Lirio Armas AlvarezService of Urology, Hospital Don Benito-Villanueva, Don Benito, Spain.
Joel Davis Osorio ManyariService of Surgery, Hospital Can Misses, Ibiza Town, Spain.
Francisco Onieva GonzalezService of Surgery, Hospital Don Benito-Villanueva, Don Benito, Spain.
Sjaak PouwelsDepartment of Surgery, Bielefeld University, Bielefeld, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fifteen to forty% of patients experience recurrent weight gain (RWG) after metabolic bariatric surgery (MBS). Glucagon-like peptide receptor agonists (GLP-1 RAs) are effective treatments for obesity in nonsurgical patients. To assess the effects of semaglutide and tirzepatide after MBS, we conducted a meta-analysis of data from inception to August 2025. Eight retrospective studies and 964 patients were included. The percentage total weight loss (%TWL) was - 10.97% [95% CI, - 13.41 to - 8.53; p < 0.05] for semaglutide and - 13.63% [95% CI, - 22.59 to - 4.67; p < 0.05] for tirzepatide. The evidence suggests that semaglutide and tirzepatide result in weight reduction in patients with RWG after MBS.

Indexed as

Bariatric SurgeryGlucagon-Like PeptidesObesity, MorbidTirzepatideWeight GainGlucagon-Like Peptide 1HumansRecurrenceSemaglutideTreatment OutcomeWeight LossGlucagon-Like Peptide 1Glucagon-Like PeptidesSemaglutideTirzepatide

Identifiers

PMID41313431

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.